Soleno Therapeutics Stock Alpha and Beta Analysis
| SLNO Stock | USD 58.34 1.12 1.96% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Soleno Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Soleno Therapeutics over a specified time horizon. Remember, high Soleno Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Soleno Therapeutics' market risk premium analysis include:
Beta 1.12 | Alpha 0.26 | Risk 2.94 | Sharpe Ratio 0.14 | Expected Return 0.4 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Soleno |
Soleno Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Soleno Therapeutics market risk premium is the additional return an investor will receive from holding Soleno Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Soleno Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Soleno Therapeutics' performance over market.| α | 0.26 | β | 1.12 |
Soleno Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Soleno Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Soleno Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Soleno Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Soleno Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Soleno Therapeutics shares will generate the highest return on investment. By understating and applying Soleno Therapeutics stock market price indicators, traders can identify Soleno Therapeutics position entry and exit signals to maximize returns.
Soleno Therapeutics Return and Market Media
The median price of Soleno Therapeutics for the period between Thu, Aug 29, 2024 and Wed, Nov 27, 2024 is 52.73 with a coefficient of variation of 6.51. The daily time series for the period is distributed with a sample standard deviation of 3.4, arithmetic mean of 52.18, and mean deviation of 2.92. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Soleno Therapeutics initiated with bullish view at H.C. Wainwright, heres why SLNO | 09/03/2024 |
2 | Disposition of 7 shares by Yen Kristen of Soleno Therapeutics at 48.3 subject to Rule 16b-3 | 09/10/2024 |
3 | Disposition of 888 shares by Patricia Hirano of Soleno Therapeutics at 41.6671 subject to Rule 16b-3 | 09/20/2024 |
4 | Disposition of 1359 shares by Patricia Hirano of Soleno Therapeutics at 36.4853 subject to Rule 16b-3 | 09/25/2024 |
5 | Why Soleno Therapeutics Stock Blasted 9 percent Higher Today | 10/08/2024 |
6 | Soleno Therapeutics Clears Technical Benchmark, Hitting 90-Plus RS Rating | 10/09/2024 |
7 | Soleno Therapeutics Pioneering Treatment for Prader-Willi Syndrome with DCCR | 10/16/2024 |
8 | Acquisition by Anish Bhatnagar of 100000 shares of Soleno Therapeutics at 36.7 subject to Rule 16b-3 | 10/18/2024 |
9 | Soleno Therapeutics to Participate in Upcoming November Investor Conferences | 10/28/2024 |
10 | Soleno Therapeutics GAAP EPS of -1.83 misses by 1.22 | 11/07/2024 |
11 | Heres Why Were Not At All Concerned With Soleno Therapeutics Cash Burn Situation - Yahoo Finance | 11/12/2024 |
12 | Perceptive Advisors LLC Increases Stake in Soleno Therapeutics Inc | 11/15/2024 |
13 | Soleno Therapeutics Clears Key Benchmark, Hitting 90-Plus RS Rating | 11/25/2024 |
About Soleno Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Soleno or other stocks. Alpha measures the amount that position in Soleno Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Payables Turnover | 0.62 | 0.59 | Days Of Inventory On Hand | 183.66 | 174.48 |
Soleno Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Soleno Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Soleno Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Soleno Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Soleno Therapeutics. Please utilize our Beneish M Score to check the likelihood of Soleno Therapeutics' management manipulating its earnings.
| 19th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 19th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Soleno Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Soleno Therapeutics Backtesting, Soleno Therapeutics Valuation, Soleno Therapeutics Correlation, Soleno Therapeutics Hype Analysis, Soleno Therapeutics Volatility, Soleno Therapeutics History and analyze Soleno Therapeutics Performance. To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Soleno Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.